CAMZYOS and placebo were administered orally, once a day. Dosage was monitored and adjusted (as needed) at weeks 8 and 12 to optimize patient response (decrease in LVOT gradient with Valsalva maneuver) and maintain LVEF ≥50%
ACC=American College of Cardiology; AHA=American Heart Association; BB=beta blocker; CCB=calcium channel blocker; HCM=hypertrophic cardiomyopathy; LVEF=left ventricular ejection fraction; LVOT=left ventricular outflow tract; NYHA=New York Heart Association; SRT=septal reduction therapy.
The primary endpoint* was a composite of patients who:
NYHA class Il with exertion-induced syncope or near syncope
ORNYHA class III or IV
ANDA dynamic LVOT gradient at rest or with provocation of ≥50 mmHg
After 16 weeks, all patients, including those who received placebo, were offered the opportunity to transition into the active-controlled phase of VALOR-HCM and receive CAMZYOS. The vast majority (95%) of all patients, including 93% of those in the placebo group, chose to continue in this active phase of the trial rather than proceed with SRT.2
KCCQ-23–CSS=Kansas City Cardiomyopathy Questionnaire (23-item version) Clinical Summary Score; LVOT=left ventricular outflow tract; NT-proBNP=N-terminal pro B-type natriuretic peptide; NYHA=New York Heart Association.
Values in the table are mean (SD) or n (%) | CAMZYOS (n=56) | Placebo (n=56) |
---|---|---|
Age, years | 59.8 ± 14.2 | 60.0 ± 10.5 |
Sex | ||
Male | 29 (51.8) | 28 (50.0) |
Female | 27 (48.2) | 28 (50.0) |
Race* | ||
White | 48 (85.7) | 52 (92.9) |
Black | 3 (5.4) | 0 (0) |
Asian |
2 (3.6) |
0 (0) |
Unspecified or other | 3 (5.4) | 4 (7.1) |
Duration of obstructive HCM disease, years | 7.5 ± 9.4 | 6.7 ± 7.4 |
Medical history | ||
Family history of HCM | 17 (30.4) | 15 (26.8) |
Atrial fibrillation |
11 (19.6) |
8 (14.3) |
Syncope or presyncope | 29 (51.8) | 30 (53.6) |
Internal cardioverter defibrillator | 9 (16.1) | 10 (17.9) |
NYHA functional class | ||
Class II with exertional syncope | 4 (7.1) | 4 (7.1) |
Class III or higher
The majority of patients were |
52 (92.9) | 52 (92.9) |
The majority of patients were NYHA class III or higher (93%)1 |
||
Type of SRT recommended | ||
Alcohol septal ablation | 8 (14.3) | 7 (12.5) |
Myectomy | 48 (85.7) | 49 (87.5) |
Background HCM therapy | ||
BB monotherapy | 26 (46.4) | 25 (44.6) |
Nondihydropyridine CCB monotherapy | 7 (12.5) | 10 (17.9) |
Disopyramide monotherapy | 0 (0.0) | 2 (3.6) |
BB and CCB | 6 (10.7) | 10 (17.9) |
BB and disopyramide | 11 (19.6) | 3 (5.4) |
CCB and disopyramide | 1 (1.8) | 2 (3.6) |
BB, CCB, and disopyramide | 2 (3.6) | 1 (1.8) |
None, medication intolerance
36%
of patients (n=20) taking
CAMZYOS and 29% of patients (n=16) in the placebo group were on combination therapy2 |
3 (5.4) | 3 (5.4) |
36%
of patients (n=20) taking CAMZYOS and 29% of patients (n=16) in the placebo group were on combination therapy2
|
||
Echocardiographic parameters | ||
LVOT gradient, mmHg | ||
Resting | 51.2 ± 31.4 | 46.3 ± 30.5 |
Valsalva | 75.3 ± 30.8 | 76.2 ± 29.9 |
Post-exercise | 82.5 ± 34.7 | 85.2 ± 37.0 |
LVEF, % | 67.9 ± 3.7 | 68.3 ± 3.2 |
Left atrial volume index, mL/m2 | 41.3 ± 16.5 | 40.9 ± 15.2 |
BB=beta blocker; CCB=calcium channel blocker; HCM=hypertrophic cardiomyopathy; LVEF=left ventricular ejection fraction; LVOT=left ventricular outflow tract; NYHA=New York Heart Association; SD=standard deviation; SRT=septal reduction therapy.
This website is best viewed
using the horizontal display
on your tablet device.
This website is best viewed
using the vertical display
on your mobile device.
References: